Castration induces parkinson disease pathologies in young male mice via inducible nitric-oxide synthase

Journal of Biological Chemistry

Volumn 288, Issue 29, 2013, Pages 20843-20855

  Khasnavis, Saurabh ^a   Ghosh, Anamitra ^a   Roy, Avik ^a   Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; DOPAMINERGIC NEURONS; MALE MOUSE; NITRIC-OXIDE SYNTHASE; PARKINSON DISEASE; WILD TYPES;

DISEASES; NEURONS; PATHOLOGY;

MAMMALS;

3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA SYNUCLEIN; ANDROSTANOLONE; CD11B ANTIGEN; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; PLACEBO; TESTOSTERONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CASTRATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; LOCOMOTION; MACROGLIA; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUBSTANTIA NIGRA; TESTOSTERONE BLOOD LEVEL; UPREGULATION;

CASTRATION; MICROGLIA; NEURODEGENERATION; NEUROINFLAMMATION; NITRIC-OXIDE SYNTHASE; PARKINSON DISEASE;

AGING; ALPHA-SYNUCLEIN; ANIMALS; ASTROCYTES; CASTRATION; DOPAMINE; DOPAMINERGIC NEURONS; DOWN-REGULATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HIPPOCAMPUS; HORMONE REPLACEMENT THERAPY; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEOSTRIATUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PARKINSON DISEASE; SUBSTANTIA NIGRA; TESTOSTERONE; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 84880562185     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.443556     Document Type: Article

References (43)

1. Olanow, C. W., and Tatton, W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22,123-144
2. Vila, M., and Przedborski, S. (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10, S58-62
3. Dauer, W., and Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889-909
4. Kurz, M. J., Pothakos, K., Jamaluddin, S., Scott-Pandorf, M., Arellano, C., and Lau, Y. S. (2007) A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. Neurosci. Lett. 429, 39-42
5. Meredith, G. E., Totterdell, S., Potashkin, J. A., and Surmeier, D. J. (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14, S112-115
6. Tan, E. K., and Skipper, L. M. (2007) Pathogenic mutations in Parkinson disease.Hum. Mutat. 28, 641-653
7. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders. Science 287,1265-1269
8. Maries, E., Dass, B., Collier, T. J., Kordower, J. H., and Steece-Collier, K. (2003) The role of a-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4, 727-738
9. Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M. F., Maidment, N. T., Levine, M. S., and Shen, J. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628-43635
10. Ghosh, A., Corbett, G. T., Gonzalez, F. J., andPahan, K. (2012) Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J. Biol. Chem. 287, 38922-38935
11. Ghosh, A., and Pahan, K. (2012) Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J. Biol. Chem. 287, 27189-27203
12. Khasnavis, S., and Pahan, K. (2012) Sodium benzoate, a metabolite of cinnamon and a food additive, up-regulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J. Neuroimmune Pharmacol. 7, 424-435
13. ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 29, 13543-13556
14. Roy, A., Ghosh, A., Jana, A., Liu, X., Brahmachari, S., Gendelman, H. E., and Pahan, K. (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One 7, e38113
15. Roy, A., and Pahan, K. (2011) Prospects of statins in Parkinson disease. Neuroscientist 17, 244-255
16. Mondal, S., Roy, A., Jana, A., Ghosh, S., Kordower, J. H., and Pahan, K. (2012) Testing NF-KB-based therapy in hemiparkinsonian monkeys. J. Neuroimmune Pharmacol. 7, 544-556
17. Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., and Pahan, K. (2007) Selective inhibition of NF-kB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 104, 18754-18759
18. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., and Przedborski, S. (1999) Inducible nitric-oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409
19. Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D. K., Ischiropoulos, H., and Przedborski, S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771
20. Gonzalez-Scarano, F., and Baltuch, G. (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22, 219-240
21. Burke, R. E. (2006) GDNF as a candidate striatal target-derived neu-rotrophic factor for the development of substantia nigra dopamine neurons. J. Neural Transm. Suppl. 70, 41-45
22. Dietz, G. P., Valbuena, P. C., Dietz, B., Meuer, K., Mueller, P., Weishaupt, J. H., and Bahr, M. (2006) Application of a blood-brain-barrier- penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 1082, 61-66
23. Kenangil, G., Orken, D. N., Ur, E., Forta, H., and Celik, M. (2009) The relation of testosterone levels with fatigue and apathy in Parkinson's disease. Clin. Neurol. Neurosurg. 111, 412-414
24. Okun, M. S., Crucian, G. P., Fischer, L., Walter, B. L., Testa, C. M., Vitek, J. L., DeLong, M. R., Hanfelt, J., and Huang, X. (2004) Testosterone deficiency in a Parkinson's disease clinic: results of a survey. J. Neurol. Neuro-surg. Psychiatry 75, 165-166
25. Mitchell, E., Thomas, D., and Burnet, R. (2006) Testosterone improves motor function in Parkinson's disease. J. Clin. Neurosci. 13,133-136
26. Okun, M. S., Walter, B. L., McDonald, W. M., Tenover, J. L., Green, J., Juncos, J. L., and DeLong, M. R. (2002) Beneficial effects of testosterone replacement for thenonmotor symptoms of Parkinson disease. Arch. Neurol. 59, 1750-1753
27. Davidoff, M. S., Ungefroren, H., Middendorff, R., Koeva, Y., Bakalska, M., Atanassova, N., Holstein, A. F., Jezek, D., Pusch, W., and Müller, D. (2005) Catecholamine-synthesizing enzymes in the adult and prenatal human testis. Histochem. Cell Biol. 124, 313-323
28. Ruffoli, R., Giambelluca, M. A., Scavuzzo, M. C., Pasquali, L., Giannessi, F., and Fornai, F. (2008) MPTP-induced parkinsonism is associated with damage to Leydig cells and testosterone loss. Brain Res. 1229, 218-223
29. Dluzen, D. E., and Ramirez, V. D. (1989) Effects of orchidectomy on nigro-striatal dopaminergic function: behavioral and physiological evidence. J. Neuroendocrinol. 1, 285-290
30. Tamäs, A., Lubics, A., Lengväri, I., and Reglodi, D. (2006) Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease. Endocrine 29, 275-287
31. rd (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology, 70, 200-209
32. Qureshi, G. A., Baig, S., Bednar, I., Södersten, P., Forsberg, G., and Siden, A. (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6,1642-1644
33. Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E. C. (1996) Nitric-oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363
34. Nathan, C. (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051-3064
35. Saha, R. N., and Pahan, K. (2006) Regulation of inducible nitric-oxide synthase gene in glial cells. Antioxid. Redox Signal. 8, 929-947
36. Akama, K. T., Albanese, C., Pestell, R. G., and Van Eldik, L. J. (1998) Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95, 5795-5800
37. Merrill, J. E., Ignarro, L. J., Sherman, M. P., Melinek, J., and Lane, T. E. (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132-2141
38. Liu, X., Jana, M., Dasgupta, S., Koka, S., He, J., Wood, C., and Pahan, K. (2002) Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J. Biol. Chem. 277, 39312-39319
39. Drapier, J. C., and Hibbs, J. B., Jr. (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-argi-nine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol. 140, 2829-2838
40. Radi, R., Beckman, J. S., Bush, K. M., and Freeman, B. A. (1991) Peroxyni-trite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266, 4244-4250
41. Wink, D. A., Kasprzak, K. S., Maragos, C. M., Elespuru, R. K., Misra, M., Dunams, T. M., Cebula, T. A., Koch, W. H., Andrews, A. W., and Allen, J. S. (1991) DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254, 1001-1003
42. Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E. Y., Palfi, S., Roitberg, B. Z., Brown, W. D., Holden, J. E., Pyzalski, R., Taylor, M. D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Deglon, N., and Aebischer, P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773
43. Hoffer, B. J., and Harvey, B. K. (2011) Is GDNF beneficial in Parkinson disease? Nat. Rev. Neurol. 7, 600-602